Suzhou, China, March 18th, 2026—CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that preclinical data for three of its proprietary pipeline assets have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, one of the most influential scientific conferences globally in cancer research. The meeting will be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, United States. The related abstracts will be published in the AACR official journal Cancer Research on April 3, 2026.
Details of the accepted abstracts and poster presentation schedule are as follows:
CS5007—an EGFR/HER3 bispecific ADC
CS5007 is a potential best-in-class (BIC) antibody-drug conjugate (ADC) in precision oncology. By simultaneously targeting EGFR and HER3, the molecule is designed to address challenges associated with tumor heterogeneity. CS5007 is being developed for multiple solid tumor indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), and triple-negative breast cancer (TNBC).
CS5008—an SSTR2/DLL3 bispecific ADC
CS5008 is a novel SSTR2/DLL3 bispecific ADC developed using CStone’s proprietary antibody and linker-payload technologies. By dual targeting SSTR2 and DLL3—two antigens frequently co-expressed in neuroendocrine neoplasms (NENs), small cell lung cancer (SCLC), and other malignancies—CS5008 is designed to address tumor heterogeneity inherent challenge to single-target therapies.
CS5006—an ITGB4-targeting ADC
CS5006 is a potential first-in-class (FIC) ADC, targeting the novel antigen integrin β4 (ITGB4). CStone identified elevated ITGB4 expression across multiple tumor types—including NSCLC, CRC, and SCCHN—with minimal expression observed in normal tissues. This profile indicates a wide therapeutic window and significant clinical potential.
About CStone
CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring ADCs, multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com.
IR contact: ir@cstonepharma.com
PR contact: pr@cstonepharma.com
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.
Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.
